Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Staphylococcus and Neisseria Tablets in stable bronchiectasis
ChiCTR2500102639Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of staphylococcus albus + neisseria catarrhalis in bronchiectasis (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Number of acute exacerbations. Started May 2025; status: recruiting.
02
Drugs
staphylococcus albus + neisseria catarrhalis
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ChiCTR2500102639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102639.